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Summary Here we report that the slow-transforming helper component of Friend murine leukaemia virus
(Fr-MLV), which produces lymphoid leukaemias in normal mice, induces erythroleukaemia in mice given
syngeneic pituitary grafts (SPG). Newborn mice were infected with Fr-MLV and, at one month of age, were
transplanted with two pituitary glands under the kidney capsule. Sham-operated infected mice and uninfected
transplanted mice served as controls. SPG selectively reduced the mean survival times of infected mice.
Histolpathology showed that, while most infected non-transplanted mice developed lymphoid leukaemias,
virtually all Fr-MLF-infected mice given SPG developed erythroleukaemias. Experiments in vitro showed that
Fr-MLV infection markedly depressed concanavalin A induced DNA synthesis in cells from spleen, thymus
and lymph nodes. Addition of prolactin or growth hormone further suppressed lectin-induced mitogenesis of
lymphoid cells from infected mice, but failed to influence the response of uninfected controls. These
experiments indicate that, in mice, pituitary hormones modulate the development and the histological features
of Fr-MLV induced leukaemias, and suggest that endocrine-immunological interactions play a role in
retrovirus induced tumorigenesis.
In previous studies on the interference between mammary
tumour virus and Friend leukaemia viruses in mice (FLV;
Basolo et al., 1985), we noticed that adult BALB/c mice
infected with the slow-transforming helper component of
FLV (designed Fr-MLV) developed erythroleukaemias when
given syngeneic pituitary grafts (SPG). The peculiarity of this
finding is that Fr-MLV does induce lymphoid leukaemias in
normal animals. Our interest in this finding was revived by
recent reports on the possibility of a heightened incidence of
leukaemias in growth hormone (GH) deficient children
treated with pituitary and/or recombinant GH (Watanabe et
al., 1988; Frisch et al., 1988; Dean, 1988; Butenandt, 1988;
Ogawa et al., 1988; Sasaki et al., 1988). Although it is
uncertain whether a relationship exists between
hypopituitarism, GH treatment and leukaemia, it has been
proposed that GH treatment might interact with environmen-
tal agents, such as viruses, to produce neoplasias (Report of
the International Workshop on GH and Leukaemia, 1988).
It is now becoming clear that functional interactions do
occur between the endocrine and the immune system (for a
review see Berczi & Kovacs, 1987). For instance, lymphoid
cells can produce ACTH in response to different stimuli
(Blalock, 1987), receptors for steroid hormones are present in
lymphoid cells of all species (Homo-Delarche & Duval,
1987), human lymphocytes and cell lines bear receptors for
insulin and GH (Lesniak et al., 1987; Gauwerky et al., 1980),
macrophages are stimulated by GH to produce the superox-
ide anion (Edwards et al., 1988).
In experimental models, the hormone dependence of lym-
phoid tumors has long been known: the incidence of spon-
taneous lymphomas is increased by oestrogens in various
animals (Noble, 1977) and the development of oestrogen-
induced lymphomas in NB rats is suppressed by drugs
interfering with the secretion of pituitary hormones (Noble et
al., 1977, 1980). Conversely, hypopysectomy reduces the
incidence of leukaemia following infection of rats with Gross
virus and causes chemically induced leukaemias to regress
(Benteley et al., 1974; Huggins & Oka, 1972; Huggins &
Veda, 1984). In mice, SPG have been found to favour the
development of chemically-induced leukaemias (Karande &
Ranadive, 1973), and GH and prolactin (PRL) have been
shown to stimulate the growth of cultured erythroleukaemia
cells (Golde et al., 1978). However, the precise mechanisms
by which pituitary hormones modulate haemopoietic malig-
nancies are still largely unknown.
This information encouraged our study on the relationship
between pituitary hormones and retrovirus-induced
leukaemias. Purposely, we investigated the neoplasias
induced by the slow transforming helper component of FLV,
since this agent consistently causes lymphoid leukaemias with
a long latent period. It appeared that during this long time
endocrine-immunological interactions could modulate the
pathogenetic process. Here we report that-under pituitary
stimulation-the pathological effects of Fr-MLV switch from
the production of lymphoid leukaemia to that of tumours
classifiable as erythroleukaemia, akin to those induced by the
acutely transforming, replication defective, spleen focus form-
ing component of FLV (SFFV).
Materials and methods
Animals
Inbred virgin female Balb/c mice bred and maintained in our
mouse colony were used throughout. The animals were
housed 3-4 per cage and received a standard maintenance
diet and water ad libitum.
Virus
Fr-MLV was originally isolated by end point dilution from a
stock of an NB-tropic, anaemia inducing strain of FLV
(Rowson & Parr, 1970). Fr-MLV was propagated in vivo in
adult BALB/c mice and checked free of contamination by
both SFFV (absence of marked and rapidly progressing
splenomegaly in adult mice, no development of eryth-
roleukaemia) and the lactic dehyrogenase virus (infected mice
have normal LDH levels). Virus preparation consisted of
filtered plasma with a titer of 3 x I05 PFU ml-' as tested on
monolayers of murine FG 10 (S+L-) cells (Toniolo et al.,
1984). This strain has been extensively used in previous work
and is immunosuppressive in adult as well as in newborn
mice (Bendinelli et al., 1985). In our mice, the induction of
erythroleukaemia by Fr-MLV depends on the age of animals
at the time of infection. Mice older than 2-3 days never
develop erythroleukaemia; however, the disease occurs when
mice are infected within 24 h from birth (unpublished obser-
vations in agreement with those of Oliff et al., 1981; Ruscetti
et al., 1981; Shibuya & Mak, 1982).
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Experimentalprocedure
Each experimental group consisted of 20 mice. Seven to
10-day-old female Balb/c mice were injected intraperitoneally
(i.p.) with a very low dose of Fr-MLV (10-30 plaque form-
ing units in 50 l). At 28-30 days of age, pituitary trans-
plants or sham operations were performed under general
anaesthesia (Innovar-Vet plus Ketalar and atropine sul-
phate). Pituitary donors were uninfected male mice of the
same strain and age. Pituitaries were removed aseptically
from the base of brain with small tweezers (i.e. the type used
for electron microscopy) and placed in sterile phosphate-
buffered saline. Two entire pituitaries were then inserted
under the right kidney capsule of each recipient. Before this,
the kidney capsule had been slightly lanced with a 23-G
needle. Sham-operated mice were subjected to the same sur-
gical procedure, but no pituitaries were transplanted. Control
groups consisted of (a) sham-operated Fr-MLV infected
mice, (b) pituitary transplanted uninfected mice and (c)
sham-operated uninfected mice. Infected animals were fol-
lowed until death and autopsied at that time. Uninfected
controls (b and c) were kept under observation until 18
months old. Six months after transplant, plasma PRL and
GH levels were determined in a few mice by RIA with sheep
PRL and rat GH as standards. RIA reagents were obtained
from Technogenetics (Milan, Italy; PRL) and from National
Pituitary Agency (GH).
Histopathology
At autopsy, the right kidney of each transplanted mice was
fixed in buffered formalin and stained with H & E to check
for the viability of SPG. Thymus, spleen, inguinal and
mesenteric lymph nodes were fixed in buffered-formaline and
embedded in resin. Sections of 2pm were stained with
haematoxylin-eosin and Giemsa stain. Spleen touch prepara-
tions were air-dried, briefly fixed in methanol and stained in
Giemsa. Formalin vapour fixation was used for the following
histochemical stains: (1) Sudan black B, (2) a-naphthyl
acetate esterase, (3) a-naphthyl butyrate esterase, (4) perox-
idase and (5) benzidine. According to Chesebro et al (1983),
the leukaemia process was classified as erythroid if over 10%
of cells were positive for x-naphthyl butyrate esterase, as
myeloid if more than 10% of cells were positive with Sudan
black or as lymphoid if more than 80% of cells were negative
for both stains. In the latter case, interpretation after Giemsa
staining was consistent with this conclusion. Mice whose
spleen cells met two of these criteria were designed as having
mixed leukaemias. Haematocrits and leukocyte counts were
obtained from all mice within 6 months of infection.
Lymphocyte proliferation assay
Dissociated cells from spleen, thymus and inguinal lymph
nodes were obtained from 6-month-old infected and
uninfected mice given or not given SPG. Each well of round-
bottom 96-well mictrotitre plates (Flow Laboratories, Irvine,
UK) received 5 x 105 cells in 100 I of RPMI-1640 medium
supplemented with 10% heat-inactivated fetal bovine serum,
2 mM L-glutamine, 5 x 10-5M 2-mercaptoethanol and
50tLg ml-' gentamicin (Flow). Fifty plA of sheep PRL (Sigma,
St Louis, MO, USA; 32 IU mg-') or rat GH (kind gift of the
National Pituitary Agency; 1.4 IU mg-') diluted in complete
medium were added to appropriate wells at the final concent-
ration of 60 ng ml`' (PRL) or 30 ng ml-' (GH): control wells
received 50Al of medium. Pilot experiments had shown that
these physiological concentrations did not alter the pro-
liferative response of spleen cells from uninfected mice to
phytohaemagglutinin or concanavalin A (PHA and Con A;
both chromatographically purified, Pharmacia, Uppsala,
Sweden). Con A, 0.5 pg in 50pL of medium (or medium
alone), was added to all cultures which were then incubated
at 37°C in air with 5% CO2. Three days later, the cultures
were pulsed with 0.5 iCi of 3H-thymidine (3H-TdR; NEN,
Bad Homburg, FRG) for 18 h and the cells were harvested
and processed (Automash, Dynatech, Alexandra, VA, USA).
Radioactivity was measured by liquid scintillation and the
results were expressed as counts per minute (c.p.m.) obtained
from triplicate cultures of 3-4 mice (mean ± standard devia-
tion).
Results
Survival times ofFr-ML V infected mice given or not SPG
As shown in Figure 1, the life expectancy of Fr-MLV
infected mice given SPG was significantly reduced as com-
pared to that of sham-operated infected mice. In particular,
the mean survival times were 299 ± 70 days for sham-
operated infected mice and 208±54 days for infected mice
given SPG (P<0.001; Kolmogorov-Smirnov non-parametric
test). All Fr-MLV infected mice receiving pituitary trans-
plants were dead by 300 days of age, while only 35% of mice
of the control group were dead by the same time. The spleen
weights of infected and transplanted mice were higher than
those of sham-operated infected animals (1848 ± 568 mg vs
1310 ± 38 mg; P<0.05). Survival times of uninfected control
groups (sham-operated or transplanted mice) were in all
cases longer than 18 months, and their spleen weight were
always lower than 300 mg. At autopsy, no spontaneous
neoplasias were found in these animals.
Plasma levels of PRL and GH were measured in a few
transplanted mice. The mean levels of PRL were significantly
higher in SPG recipients than in sham-operated mice
(35.7 ± 7.2 vs 6.6 ± 1.8, respectively; mean ± s.e.m., n = 5 in
both groups), while GH levels were approximately the same
in both groups (26.4 ± 8.2 vs 23.3 + 5.2; mean ± s.e.m.).
These results are in good agreement with published data
which indicate that PRL is the main product of ectopically
transplanted pituitaries (Labrie et al., 1978; Fernandez-Ruiz
et al., 1987).
Histopathology
At the time of death (i.e. 100-270 days after transplant),
SPG take was assessed in each animal by histologic examina-
tion of the right kidney. By morphological criteria, trans-
planted pituitaries were clearly viable in all infected mice.
The histopathology of Fr-MLV induced neoplasias was
markedly different in the two groups of animals. In sham-
operated infected mice, the neoplastic process was essentially
confined to the spleen and lymph nodes; histopathological
changes were not found in the thymus. According to the
criteria of Chesebro et al. (1983), morphological studies
together with haematological data obtained before death
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Figure 1 Survival times of female BALB/c mice injected with a
very low dose of Fr-MLV at 7- 10 days of age. Mice given
syngeneic pituitary grafts (A) and sham-operated animals (0).
Total of 18 or 20 mice per group. All uninfected control mice
given or not pituitary grafts lived longer than 18 months.PITUITARY HORMONES AND MLV-INDUCED LEUKAEMIAS 843
showed that 6/17 animals had lymphoid leukaemia, 8/17 had
mixed lymphoid and myeloid leukaemia, 2/17 had myeloid
leukaemia, and one had mixed lymphoid-erythroid leukae-
mia. The neoplastic involvement of the spleen was predomin-
antly periarteriolar and the lymphatic follicles were replaced
by leukaemic cells which were adjacent to the fibrous
trabeculae and infiltrated the red pulp (Figure 2a). In con-
trast, 18 out of 20 infected mice given SPG showed erythroid
leukaemias characterised by hyperbasophilic small round
cells infiltrating the red pulp of the spleen and liver sinusoids,
as well as by large atypical cells with clear cytoplasms and
vesciculated nuclei (Figure 2 b-d); over 10% of spleen cells
were positive for a-naphthyl butyrate esterase (Figure 2 e).
The lymph nodes and thymuses oferythroleukaemic mice did
not show neoplastic involvement. In this group, only 2/20
animals had lymphoid leukaemia.
Figure 2 a, Spleen of a sham-operated mouse 8 months after
infection with Fr-MLV: lymphoid leukaemia in a periarteriolar
area (H & E, x 300). b and c, Erythroleukaemia in the spleens of
7-month-old Fr-MLV infected mice given syngeneic pituitary
grafts: hyperbasophilic small round cells interspersed among large
atypical cells (H & E: b x 300; c x 500). d and e, Spleen touch
preparations from Fr-MLV-infected mice given SPG d, Giemsa
stain; e, positive staining for a-naphthyl butirate esterase;
both x 1,000).
PRL and GH inhibit theproliferation in vitro ofFr-MLV
infectedlymphoid cells
The effect of physiological concentrations of PRL and GH
on the in vitro DNA synthesis of lymphoid cells from mice
infected with Fr-MLV 6 months earlier was studied.
Preliminary experiments had shown that physiological con-
centrations of sheep PRL (< 100 ngml-') and of rat GH
(<60 ngml-') did not influence the PHA- or Con A-induced
mitogenesis of lymph node cells obtained from uninfected
mice given or not SPG. When spleen, lymph node, or thymus
cells from sham-operated infected mice were stimulated with
Con A, their mitogenic response was markedly depressed as
compared to that of uninfected controls. Most notably, the
addition of PRL and GH further suppressed the response of
infected cells, virtually without altering that of uninfected
cells (Table I). The same results were obtained in two other
experiments. PRL depressed the response of spleen thymus,
or lymph node cells by at least 50%, while GH had similar,
but less pronounced effects. In the case of uninfected cells,
PRL and GH significantly enhanced DNA synthesis in spleen
cultures not stimulated with Con A (in agreement with data
of Berczi & Nagy, 1987), but depressed it by about 15% after
Con A stimulation. PRL and GH did not modify the res-
ponse of uninfected lymph node and thymus cells. This
indicates that, among the lymphatic tissues examined, only
spleen cells are responsive to these hormones.
Discussion
This study indicates that ectopic pituitary transplantation
favours the development of Fr-MLV induced leukaemias and
switches their histotype from predominantly lymphoid to
erythroid. That Fr-MLV infection may induce eryth-
roleukaemias in susceptible hosts has already been noted in
BALB/c and NIH-Swiss mice infected at birth with high
doses of virus (Oliff et al., 1981; Ruscetti et al., 1981;
Shibuya et al., 1982). Shibuya and Mak (1982) showed that a
single dominant locus (designed Fv6) controls eryth-
roleukemia induction by this virus in newborn mice. Fv6
appears to have no influence on adult mice (Ruscetti et al.,
1981; and personal observations) and is distinct from the
other loci (Fv2 and Fv5) which are specific for SFFV and
regulate the proliferation of erythroid precursors. Fv6 is
specific for Fr-MLV and probably acts on haemopoietic
tissue differentiation (Shibuya & Mak, 1982). Whatever its
mode of action, BALB/c mice (which are Fv6-) are con-
sidered permissive to the induction of erythroleukaemia when
infected within 1 day of birth, whereas in our experiments
BALB/c mice infected at 7 to 10 days of age failed to develop
erytholeukaemia if not given pituitary grafts.
This apparent discrepancy may derive from the peculiar
experimental design adopted in this study. Purposely, we
injected mice older than 1 day of age with extremely low
doses of virus in order to delay tumour development and
leave enough time for endocrine mechanisms to play their
Table I Effects of PRL and GH on the proliferation in vitro of lymphoid cells from uninfected and Fr-MLV-infected mice (incorporation of
3H-thymidine; c.p.m. x 10-3)
Uninfected mice Infected mice
Organ Mitogen Medium PRL GH Medium PRL GH
Spleen None 905 ± 250 5,370 500* 5,440 570* 980 30 470 80* 670 320
Con A 61,450 ± 6,830 54,040 ± 1,330 52,420 ± 1,930 3,530 ± 470 1,520± 230* 1,480 ± 150* Lymph node None 140 70 90 20 160 50 310 70 460 20 470 20
Con A 103,730± 4,220 105,720 ± 6,810 105,870 ± 7,880 1,430± 230 710± 60* 1,040 + 250* Thymus None 310 130 190±40 280 110 140±80 390 130 320±70
Con A 1,970 ± 690 1,640 ± 544 2,220 + 990 840 ± 160 200 ± 30* 80 ± 10*
Six-minth-old mice were notgiven syngeneic pituitary grafts. Hormoneconcentrations: PRL 60 ngmlh', GH 30 ngmlh'. Mean ± s.d. oftriplicate cultures from 3-4animals. See Materialsandmethodsfordetails. Notethattheresponseofcellsfrominfected micehasbeeninallcasessignificantly lower than that ofcells from uninfected animals. *Significantly different from control cultures receiving no hormones (P<0.05).844 G. FONTANINI et al.
role. This choice might have slowed down the transformation
and proliferation of target cells to the point that the whole
process occurred in adult life, when the influence of certain
developmental controls on haemopoietic tissues might have
become negligible. It can be envisaged that, in mice given
SPG, these developmental controls remain active through the
adult age or, alternatively, that they are represented by high
levels of pituitary hormones.
Since ectopic pituitary glands are known to secrete large
amounts of PRL, while the production of other pituitary
hormones is grossly impaired (Labrie et al., 1978; Bercz &
Nagy, 1987), it seems that, in this system, PRL favoured
directly the virus induced transformation and proliferation of
erythroid precursors. Pregnancy, which is associated with
increased levels of PRL, is also characterised by enhanced
erythropoiesis, and it is known that PRL and GH control
haemolymphopoietic cells through the c-myc gene (Berczi &
Nagy, 1987; Gout et al., 1980). Thus, Fr-MLV transformed
erythroid precursors might express PRL receptors responsible
for their pituitary dependency, as in the case of the Nb2 rat
lymphoma which is dependent on PRL for growth in vivo
(Gout et al., 1980). This hypothesis awaits confirmation.
An alternative explanation would be that high levels of
pituitary hormones could favour indirectly the growth of
virally induced tumours by suppressing the immune response
to the tumour itself. With regard to normal hosts, this
hypothesis seems untenable since PRL and GH have been
shown to potentiate-not to depress-immune functions
(Berczi & Nagy, 1987). Even in our experiments in vitro, both
PRL and GH failed to depress the proliferative response of
uninfected lymphoid cells. However, the activation of Fr-
MLV infected lymphoid cells was markedly inhibited by both
hormones. This observation suggests that also in vivo PRL
and GH could worsen viral induced immunodeficiency and
favour tumour progression. Although this may appear not
significant in view of the profound immunosuppression pro-
duced by Fr-MLV some months after infection, the hormone
mediated immunosuppression might favour the spread of
virus and of virus transformed cells in the early phase of
infection, when only mild immunosuppression is found (Ben-
dinelli et al., 1985).
In conclusion, recent clinical observations together with
new experimental approaches begin to clarify the interplay
between transforming viruses, the immune and the endocrine
systems. Our model system, which closely mimics the human
situation due to the long latency of the viral process,
indicates that pituitary hormones may act directly by
stimulating the growth of transformed cells, and indirectly by
lowering the host's immune defences.
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